Dana-Farber Cancer InstituteFinal Overall Survival Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan in Patients with HR+/HER- Metastatic Breast Cancer

Could sacituzumab govitecan be the new standard in treating endocrine refractory metastatic hormone receptor-positive breast cancer?

Delve into the latest findings from the TROPiCS-02 study, a phase three trial in patients with metastatic hormone receptor-positive breast cancer, presented by Dr. Sara Tolaney at ASCO 2023.

Key Points:

• The TROPiCS-02 study is a phase three trial involving patients with metastatic hormone receptor-positive breast cancer.
• Patients were randomized to receive either sacituzumab govitecan or a treatment of the physician’s choice.
• The study showed a consistent improvement in progression-free survival from about four months to 5.5 months.
• Overall survival improved significantly, going from 11.2 months to 14.5 months.

Additional Points:

• The patient population had progressed on prior endocrine therapy and had received prior taxane.
• Patients could have received 2 to 4 prior lines of chemotherapy in the metastatic setting.

Conclusion:

• The TROPiCS-02 study suggests that sacituzumab govitecan offers a significant survival benefit for patients with endocrine refractory metastatic hormone receptor-positive breast cancer, positioning it as a new standard treatment option.

Radiation Oncology Latest Posts

• New Research Sheds Light on a Surprising Connection Between COVID-19 and Cancer RegressionDecember 3, 2024
• What Is Bladder Cancer?December 3, 2024
• Big Year in SCLC: “Unprecedented” Results Lead to New Standard of CareDecember 3, 2024
• Genetic Tests Identify Risk of Irinotecan-Induced ToxicityDecember 3, 2024

Did You Know?
According to the American Cancer Society, hormone receptor-positive breast cancer is the most common type of breast cancer, accounting for about 2 out of 3 cases.